Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?  Yahoo Finance

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

How did AUPH's Q3 2024 earnings surprise impact short-term traders?  AInvest

How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

Click here to get full coverage on Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week  simplywall.st

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st

Click here to get full coverage on Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (AUPH) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH)  Seeking Alpha

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha

Click here to get full coverage on Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - Business Wire

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025  Business Wire

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - Business Wire

Click here to get full coverage on With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns  Yahoo Finance

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance

Click here to get full coverage on From $78M Loss to Profitable: How Aurinia's LUPKYNIS Drug Transformed Its Financials - Stock Titan

From $78M Loss to Profitable: How Aurinia's LUPKYNIS Drug Transformed Its Financials  Stock Titan

From $78M Loss to Profitable: How Aurinia's LUPKYNIS Drug Transformed Its Financials - Stock Titan

Click here to get full coverage on What does AUPH's Q1 2025 forecast suggest for future growth? - AInvest

What does AUPH's Q1 2025 forecast suggest for future growth?  AInvest

What does AUPH's Q1 2025 forecast suggest for future growth? - AInvest

Click here to get full coverage on Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH)  Seeking Alpha

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha

Click here to get full coverage on Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st

Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues  simplywall.st

Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st

Click here to get full coverage on (AUPH) Trading Report - news.stocktradersdaily.com

(AUPH) Trading Report  news.stocktradersdaily.com

(AUPH) Trading Report - news.stocktradersdaily.com

Click here to get full coverage on Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - Yahoo Finance

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?  Yahoo Finance

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - Yahoo Finance

Click here to get full coverage on Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality  simplywall.st

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st

Click here to get full coverage on Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH)  Seeking Alpha

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha

Click here to get full coverage on Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March  Yahoo Finance

Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Click here to get full coverage on retail investors who own 52% along with institutions invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw increase in their holdings value last week - simplywall.st

retail investors who own 52% along with institutions invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw increase in their holdings value last week  simplywall.st

retail investors who own 52% along with institutions invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw increase in their holdings value last week - simplywall.st

Click here to get full coverage on Aurinia (AUPH) Upgraded to Buy: Here's Why - Yahoo Finance

Aurinia (AUPH) Upgraded to Buy: Here's Why  Yahoo Finance

Aurinia (AUPH) Upgraded to Buy: Here's Why - Yahoo Finance

Click here to get full coverage on Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates  Yahoo Finance

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now?  Yahoo Finance

Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on Aurinia Pharmaceuticals: A Bullish Double Play in the Russell Reconstitution - AInvest

Aurinia Pharmaceuticals: A Bullish Double Play in the Russell Reconstitution  AInvest

Aurinia Pharmaceuticals: A Bullish Double Play in the Russell Reconstitution - AInvest

Click here to get full coverage on When Will Aurinia Report Q4 Earnings? Key Date and Details for Investors - Stock Titan

When Will Aurinia Report Q4 Earnings? Key Date and Details for Investors  Stock Titan

When Will Aurinia Report Q4 Earnings? Key Date and Details for Investors - Stock Titan

Click here to get full coverage on Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks

Aurinia Pharmaceuticals Approves New Equity Incentive Plan  TipRanks

Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks

Click here to get full coverage on 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms  Yahoo Finance

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance

Click here to get full coverage on (AUPH) Technical Data - news.stocktradersdaily.com

(AUPH) Technical Data  news.stocktradersdaily.com

(AUPH) Technical Data - news.stocktradersdaily.com

Click here to get full coverage on (AUPH) Investment Report - news.stocktradersdaily.com

(AUPH) Investment Report  news.stocktradersdaily.com

(AUPH) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Yahoo Finance

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025  Yahoo Finance

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Yahoo Finance

Click here to get full coverage on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript  MSN

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN

Click here to get full coverage on Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting  Business Wire

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire

Click here to get full coverage on Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - Business Wire

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)  Business Wire

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - Business Wire

Click here to get full coverage on Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks

Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study  TipRanks

Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks

Click here to get full coverage on (AUPH) Trading Signals - news.stocktradersdaily.com

(AUPH) Trading Signals  news.stocktradersdaily.com

(AUPH) Trading Signals - news.stocktradersdaily.com

Click here to get full coverage on Aurinia Pharmaceuticals: This Recovery Can Continue (AUPH) - Seeking Alpha

Aurinia Pharmaceuticals: This Recovery Can Continue (AUPH)  Seeking Alpha

Aurinia Pharmaceuticals: This Recovery Can Continue (AUPH) - Seeking Alpha

Click here to get full coverage on Aurinia Pharmaceuticals' AUR200 Phase 1 Data: A Catalyst for Growth or a Risk to Avoid? - AInvest

Aurinia Pharmaceuticals' AUR200 Phase 1 Data: A Catalyst for Growth or a Risk to Avoid?  AInvest

Aurinia Pharmaceuticals' AUR200 Phase 1 Data: A Catalyst for Growth or a Risk to Avoid? - AInvest

Click here to get full coverage on Aurinia Pharmaceuticals Inc.(NasdaqGM: AUPH) added to Russell 2000 Defensive Index - MarketScreener

Aurinia Pharmaceuticals Inc.(NasdaqGM: AUPH) added to Russell 2000 Defensive Index  MarketScreener

Aurinia Pharmaceuticals Inc.(NasdaqGM: AUPH) added to Russell 2000 Defensive Index - MarketScreener

Click here to get full coverage on Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations  Yahoo Finance

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Click here to get full coverage on Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade  Investor's Business Daily

Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Click here to get full coverage on Company News for May 13, 2025 - Yahoo Finance

Company News for May 13, 2025  Yahoo Finance

Company News for May 13, 2025 - Yahoo Finance

Click here to get full coverage on Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting  Business Wire

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire

Click here to get full coverage on Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $11M Stock Buy: Retail Confidence Spikes - Stocktwits

Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $11M Stock Buy: Retail Confidence Spikes  Stocktwits

Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $11M Stock Buy: Retail Confidence Spikes - Stocktwits

Click here to get full coverage on Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks

Glass Lewis Supports Aurinia’s Proposals for 2025 AGM  TipRanks

Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks

Click here to get full coverage on Aurinia Pharmaceuticals: Institutional Bull Run or Overvalued Risk? - AInvest

Aurinia Pharmaceuticals: Institutional Bull Run or Overvalued Risk?  AInvest

Aurinia Pharmaceuticals: Institutional Bull Run or Overvalued Risk? - AInvest

Click here to get full coverage on Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept - TipRanks

Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept  TipRanks

Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept - TipRanks

Click here to get full coverage on Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results - TipRanks

Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results  TipRanks

Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results - TipRanks

Click here to get full coverage on Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com

Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares  Investing.com

Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com

Click here to get full coverage on Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com

Aurinia Pharma stock hits 52-week high at $9.76  Investing.com

Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com

Click here to get full coverage on Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings  TipRanks

Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

Click here to get full coverage on Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com

Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223  Investing.com

Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com

Click here to get full coverage on Aurinia shares rise ahead of key autoimmune therapy data - Proactive Investors

Aurinia shares rise ahead of key autoimmune therapy data  Proactive Investors

Aurinia shares rise ahead of key autoimmune therapy data - Proactive Investors

Click here to get full coverage on Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.16, vs. FactSet Est of $0.14 - MarketScreener

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.16, vs. FactSet Est of $0.14  MarketScreener

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.16, vs. FactSet Est of $0.14 - MarketScreener

Click here to get full coverage on Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks

Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals  TipRanks

Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks

Click here to get full coverage on Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals

Aurinia Pharmaceuticals laying off dozens in Montgomery County  The Business Journals

Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals

Click here to get full coverage on Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations  Benzinga

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga

Click here to get full coverage on Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks

Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals  TipRanks

Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks

Click here to get full coverage on Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event - TipRanks

Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event  TipRanks

Aurinia Pharmaceuticals Inc (AUPH)

Price Chart

Key Statistics

Technicals

About AUPH

Latest News

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance

How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st

Advanced Charts

Top Gainers

Top Losers